Asher Bio to Present Preclinical Proof-of-Concept Data for AB248, a Highly Selective CD8-targeted IL-2 Therapy, at SITC 2021

SOUTH SAN FRANCISCO, Calif.–()–Asher Biotherapeutics, a biotechnology company developing precisely-targeted immunotherapies for cancer, autoimmune, and infectious diseases, today announced that it will present two abstracts at the Society for Immunotherapy of Cancer 36th Annual Meeting (SITC 2021), being held in Washington D.C. and virtually, November 10-14, 2021.

Collectively, the presentations demonstrate preclinical proof-of-concept for Asher Bio’s cis-targeting approach and lead program AB248. AB248 is an engineered interleukin-2 (IL-2) immunotherapy, designed specifically to target CD8+ effector T cells. Asher expects to file an investigational new drug application for AB248 in the third quarter of 2022.

Details of the presentations are as follows:

Oral Presentation:

Title: CD8-targeted IL-2 drives potent anti-tumor efficacy and promotes action of tumor specific vaccines

Authors: Hussein Sultan, PhD, Kelly Moynihan, PhD, Yuang Song, Ton Schumacher, PhD, Andy Yeung, PhD, Ivana Djuretic, PhD, and Robert D. Schreiber, PhD

Abstract Number: 578

Session: Cellular Therapies, Saturday 11/13/2021, 3:40 pm – 4:55 pm ET

Poster Presentation:

Title: Selective activation of CD8+ T cells by a CD8-targeted IL-2 results in enhanced anti-tumor efficacy and safety

Authors: Kelly Moynihan, PhD, Danielle Pappas, Terrence Park, Wei Chen PhD, Irene Ni, Paul Bessette PhD, Mike Chin, Ton Schumacher, PhD, Andy Yeung, PhD, and Ivana Djuretic, PhD

Abstract Number: 717

Session: Poster Hall E, Friday 11/12/2021, 7:00 am – 8:30 pm ET

Both abstracts will become available online on the SITC conference website beginning at 8:00 a.m. ET on Tuesday, November 9, 2021.

About Asher Bio

Asher Bio is a biotechnology company developing precisely targeted immunotherapies for cancer and other diseases. Our cis-targeting platform aims to enable selective activation of specific immune cell types, addressing the inherent limitations of otherwise pleiotropic immunotherapies that act on multiple cell types. Our approach has the potential to precisely direct different immune mediators against a range of target immune cell-types and create best-in-class immunotherapies in cancer, autoimmune and infectious diseases. Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco. For more information, please visit www.asherbio.com and follow us on Twitter @AsherBio and on LinkedIn.

Source

Recent Articles

Get a free copy of "Cracking the Generics Code"

Looks like you are using an ad-blocking browser extension. We request you to whitelist our website on the ad-blocking extension and refresh your browser to view the content.